Giving the anti-clotting drug rivaroxaban to patients for 12 weeks instead of the usual six after a blood clot in the lower leg reduces the risk of further clots developing up to two years after ...
Effect of a Community Health Worker–Led Intervention Among Low-Income and Minoritized Patients With Cancer: A Randomized Clinical Trial More than 90% of patients in each group were treated with ...
MedPage Today on MSN
DVT Assessment Strategy Safely Expands Rule-Out
A prospective validation study found that age-adjusted D-dimer thresholds can safely rule out lower extremity DVT for more ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window AMSTERDAM -- A ...
If the choice is made to anticoagulate patients with symptomatic isolated distal deep vein thrombosis (DVT), outcomes will be improved with 12 versus 6 weeks of treatment, the randomized, ...
Please provide your email address to receive an email when new articles are posted on . Adults with isolated distal deep vein thrombosis experience fewer short- and long-term adverse outcomes compared ...
Please provide your email address to receive an email when new articles are posted on . Longer vs. shorter-duration anticoagulation reduces thrombotic event risk for patients with cancer and isolated ...
The mainstay of treatment for DVT is anticoagulation therapy. However, optimal anticoagulation strategies for cancer patients with isolated distal DVT are not currently established. ONCO DVT was the ...
Rivaroxaban is an anticoagulant drug. It’s given to people at a high risk of getting dangerous blood clots to help their blood clot (thicken) more slowly. Anticoagulation is known to prevent further ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback